Denali Therapeutics Inc.

Denali Therapeutics Inc. is not a good value stock. Denali Therapeutics Inc. is not a good growth stock. Denali Therapeutics Inc. is not very popular among insiders. Denali Therapeutics Inc. is a mediocre stock to choose.
Log in to see more information.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and comme...
DNLI Fundamental Data by TradingView

News

Cantor Fitzgerald Reiterates "Overweight" Rating for Denali Therapeutics (NASDAQ:DNLI)
Cantor Fitzgerald Reiterates "Overweight" Rating for Denali Therapeutics (NASDAQ:DNLI)

Zolmax Denali Therapeutics (NASDAQ:DNLI - Get Free Report)s stock had its "overweight" rating reiterated by analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They...\n more…

Denali Therapeutics (NASDAQ:DNLI) Rating Reiterated by Cantor Fitzgerald
Denali Therapeutics (NASDAQ:DNLI) Rating Reiterated by Cantor Fitzgerald

Ticker Report Denali Therapeutics (NASDAQ:DNLI - Get Free Report)s stock had its "overweight" rating reissued by research analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They...\n more…

Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $38.33
Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $38.33

Zolmax Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat reports. One...\n more…

Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.33
Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.33

Ticker Report Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the company, Marketbeat Ratings reports...\n more…

Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Candriam S.C.A.
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Candriam S.C.A.

Ticker Report Candriam S.C.A. grew its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 62.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 726,499 shares of the company's...\n more…

FY2025 Earnings Forecast for Denali Therapeutics Inc. Issued By Leerink Partnrs (NASDAQ:DNLI)
FY2025 Earnings Forecast for Denali Therapeutics Inc. Issued By Leerink Partnrs (NASDAQ:DNLI)

Zolmax Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Denali Therapeutics in a note issued to investors...\n more…